Angiogenesis occurs during normal physiologic processes as well as under pathologic conditions such as tumor growth.
+ cells. EPC share some properties with fully differentiated endothelial cells from normal tissue, yet reverse transcription-PCR and flow cytometry reveal that EPC express higher levels of endosialin at the molecular and protein levels. The elevated expression of endosialin in EPC versus mature endothelial cells suggests that endosialin is involved in the earlier stages of tumor angiogenesis. Anti-endosialin antibodies inhibited EPC migration and tube formation in vitro. In vivo, immunohistochemistry indicated that human EPC continued to express endosialin protein in a Matrigel plug angiogenesis assay established in nude mice. Antiendosialin antibodies delivered systemically at 25 mg/kg were also able to inhibit circulating murine EPC in nude mice bearing s.c. SKNAS tumors. EPC and bone marrow -derived cells have been shown previously to incorporate into malignant blood vessels in some instances, yet they remain controversial in the field. The data presented here on endothelial genes that are up-regulated in tumor vasculature and in EPC support the hypothesis that the angiogenesis process in cancer can involve EPC. [Mol Cancer Ther 2008; 7(8) 
Introduction
Angiogenesis is required for tumor growth and physiologic studies showed that tumor vasculature is distinct from normal vasculature. For example, blood flow in tumors is irregular with circulation occurring at lower than normal rates in vessels that can be corkscrew-like or tortuous in shape resulting in high interstitial pressure (1) . Mosaicism in tumor vasculature results in greater permeability or ''leakiness'' than normal blood vessels (2) .
Serial analysis of gene expression (SAGE) analysis comparing the gene expression profiles between endothelial cells isolated from normal tissues and from tumors enables the identification of angiogenesis-related genes upregulated in malignant disease. St. Croix et al. reported a series of up-regulated genes, tumor endothelial markers (TEM), differentially expressed z10-fold by tumor endothelial cells versus normal endothelial cells (3) . Endosialin, or TEM1/CD248, expression was confined to the smaller blood vessels in many human tumors including sarcomas, carcinomas, and neuroectodermal tumors (4) , suggesting involvement in the earlier stages of angiogenesis.
Endosialin is a type I cell surface glycoprotein of 757 amino acids with a predicted molecular mass of 80.9 kDa and one transmembrane domain (5) . Endosialin interacts with extracellular matrix proteins to mediate cell adhesion and migration (6) . Endosialin has also been detected in human melanomas, squamous cell carcinomas, brain tumors, and colorectal cancer (7 -9 ). An endosialin knockout mouse was fertile with normal body weight, vasculature, and wound healing capability (10) . However, when human HCT116 colon carcinoma was implanted orthotopically into nude endosialin knockout mice, the tumor take rate was 33% versus 90% in normal nude mice. HCT116 tumors grew more slowly in the knockout mice with fewer liver metastases, indicating that endosialin can influence tumor vascular development.
Vasculature formation within tumors can arise from the cooption of existing blood vessels in close proximity to the site of malignancy. However, cells derived from the bone marrow can also home to tumorigenic sites in response to proangiogenic factors released by cancer cells and stroma. Bone marrow -derived endothelial precursor cells (EPC) have been identified in the tumor vasculature of some preclinical models (11 -13) . Importantly, EPC have recently been shown to control the angiogenic switch in mouse lung metastasis (14) . In humans, EPC have been identified in patients with multiple myeloma, astrocytomas, inflammatory breast cancer, and non-small cell lung cancer (15 -18) .
Because endosialin has been implicated in tumor angiogenesis and EPC can incorporate into tumor vasculature, we investigated the expression of endosialin, TEM, and anti-endosialin antibodies in EPC. The molecular markers that denote an EPC population remain controversial in the field. Progenitor cells in bone marrow or in circulation that express the markers CD34 and CD133 identify a subpopulation of stem cells that are capable of differentiation into more mature endothelial cells on stimulation with angiogenic factors (19) . The CD133, or AC133/Prominin-1 epitope, is a distinctive marker for EPC (20) 5 cells/mL) were grown in Iscove's modified Dulbecco's medium (IMDM; Lonza), 15% fetal bovine serum (FBS; Invitrogen), 50 ng/mL VEGF 165 (R&D Systems), 25 ng/mL basic fibroblast growth factor (bFGF; R&D Systems), and 5 units/mL heparin (Sigma) on fibronectin or native collagen I -coated flasks (BD Biosciences) to generate adherent EPC (21, 22) . After two passages, the EPC were maintained in IMDM/10% FBS without growth factors. EPC were exposed to 10 Ag/mL Ac-Dil-LDL (Biomedical Technologies) in IMDM/10% FBS for 4 h. EPC were washed twice and imaged live by fluorescent microscopy.
HMVEC and HUVEC were grown in endothelial cell basal medium/2% FBS and supplements (Lonza). SKOV3 and SKNAS cells (American Type Culture Collection) were grown in RPMI 1640/10% FBS. Cultures were propagated at 37jC with humidified 95% air/5% CO 2 .
SAGE Libraries SAGE libraries were constructed as described previously (3, 21, 23) . EPC were cultured in the absence or presence of VEGF (150 ng/mL) for 72 h before RNA extraction.
mRNA Expression by Real-time PCR EPC were harvested in Trizol reagent (1 mL) plus chloroform (200 AL). Samples were incubated at room temperature for 3 min and centrifuged at 3,000 rpm for 15 min at 4jC. The aqueous layer was extracted and mixed 1:1 with 70% ethanol. Samples were passed through a Qiagen column and prepared according to the manufacturer's instructions. RNA integrity and purity was checked by gel electrophoresis and A 260 /A 280 measurements.
Reverse transcription was done using the cDNA archive kit (Applied Biosystems). Real-time PCR analysis was done using the fluorogenic 5 ¶-nuclease assay in the ABI 7700 sequence detector (Taqman). Final concentrations of each duplicate multiplex reaction were 900 nmol/L primer, 200 nm of probe, 50 nmol/L 18S primers, and 200 nmol/L 18S probe. Cycle thresholds were converted to transcript copy numbers using a cDNA standard curve. Even loading of the samples was verified by measurement of 18S levels. Reverse transcription-PCR for TEM6 was done with SYBR Green PCR Master Mix. PCR were repeated at least once. endosialin forward primer: GCAAGTGGCGAG-CACCGCTGGCT, endosialin reverse primer: GGCAGGC-GCCCTCGAAGCCA, and endosialin probe: CGCTGGCT-GTCGACGGCTACCTGTGCCAGTT.
TEM3 forward primer: TACCAACATTTCGGCTGTGG, TEM3 reverse primer: GATACACAGGGGCCACATCT, and TEM3 probe: TGACCCCATTACCCACATGCCTC-CAGTTT.
TEM5 forward primer: AAGGCCTGCAGCCGCATCGT, TEM5 reverse primer: GCAGGTCAGGCCCACGTAGCTG, and TEM5 probe: CACGTTCCTCGCATTCACTGA-GATGTGCTGG.
TEM6 forward primer: ACCCGTGACGTCATTTTC and TEM6 reverse primer: TGTACTTGCTTCGAGCATC. TEM7 forward primer: CACCATGACGGCCGCATTGT, TEM7 reverse primer: AGGCCGGTTTTGACAGGATGC, and TEM7 probe: CTTTGCCTATAAAGAGATCCC-TATGTCTGTCCCGG.
ANTXR1/TEM8 forward primer: CCGGAGCAGGAA-TATGAATT, ANTXR1/TEM8 reverse primer: GACCCA-C A A G G C A T C G A , a n d A N T X R 1 / T E M 8 p r o b e : TCCCCCCGGAAGTGGTACTC.
TEM9 forward primer: GCAAGGACAAGAAGTG-CGTGT, TEM9 reverse primer: GATGTAGGGCAA-GGCTGTCA, and TEM9 probe: CAGTCCTCTCGGCTG-GCTGTC.
Generation of Endosialin Antibodies
The rabbit polyclonal antibody was generated from New Zealand white rabbits immunized with pDNA encoding the extracellular portion of human endosialin. Rabbits were immunized using the gene gun method and blood was collected before and after immunization. Antiendosialin rabbit IgG were purified from serum by affinity chromatography using HiTrap Protein G HP columns (GE Healthcare Life Sciences) as described by the manufacturer. Immune serum (10 mL) was mixed with 20 mL binding buffer (20 mmol/L sodium phosphate, pH 7.0) and passed through a 0.45 Am filter. Serum was applied over an equilibrated HiTrap Protein G HP column. The bound antibody was eluted with 2 to 5 column volumes of elution buffer (0.1 mol/L glycine-HCl, pH 2.7). Fractions (1 mL) were collected and neutralized with 60 AL of 1 mol/l Tris-HCl (pH 9.0). The fractions with purified antibody (as measured by A 260 ) were pooled and buffer exchanged using PD-10 desalting columns into PBS.
The monoclonal anti-human endosialin antibody is a fully human monoclonal antibody isolated after inoculation of the KM mouse (24) . The control antibody is a fully human antibody raised against dinitrophenol in the KM mouse. CHO cells were transfected with plasmid constructs expressing anti-dinitrophenol or anti-endosialin. The highest producing CHO clones or hybridoma cells were selected. CHO cells were grown in CD-CHO medium (Invitrogen) supplemented with 32 mmol/L arginine, 64 mmol/L asparagine, 8 mmol/L cysteine, 100 g/L glucose, 32 mmol/L glutamine, 64 mmol/L serine, and 16 mmol/L tyrosine. Hybridomas were seeded in PFHM medium with 5% low IgG FBS (Invitrogen) and expanded in serum-free PFHM. The antibodies from conditioned medium were captured over a protein A-Sepharose column (GE Healthcare) equilibrated with 50 mmol/L sodium phosphate, 25 mmol/L NaCl (pH 7.1), loaded, and washed first with 50 mmol/L sodium phosphate, 25 mmol/L NaCl (pH 7.1) and then with 10 mmol/L sodium succinate (pH 6.0). The column was eluted with 10 mmol/L sodium succinate (pH 3.75). The eluates with antibodies were sterile filtered through a 0.22 Am PES membrane (Whatman), formulated in 20 mmol/L histidine buffer (pH 6.0) and 0.005% PS80, and concentrated.
Immunostaining EPC were cultured in IMDM/10% FBS. EPC were washed twice with PBS, incubated with rabbit postimmune or preimmune serum on ice for 1 h, and washed twice. Secondary donkey anti-rabbit FITC antibody (1:200; Jackson Immunochemicals) was added and cells were incubated for 30 min on ice, washed twice, and imaged by fluorescent microscopy.
Flow Cytometry EPC, HMVEC, and HUVEC were collected by brief exposure to 0.25% tryspin/1 mmol/L EDTA (Invitrogen), washed twice with cold PBS/5% FBS buffer, resuspended in buffer (1 Â 10 5 -2 Â 10 5 cells/100 AL), incubated with the primary antibody for 1 h on ice, washed twice, incubated with the secondary antibody for 45 min on ice, washed twice, and resuspended (500 AL). For endosialin staining or control, the rabbit polyclonal IgG (20 Ag/mL) was used. Two micrograms of the following antibodies were applied: anti-TEM2, anti-TEM4, anti-TEM5 (ProSci), anti-TEM7, and anti-TEM-8 (Abcam). Two micrograms of antibodies were used for EPC characterization: anti-CD31, anti-CD45, anti-VE-cadherin (Abcam), and anti-VEGFR2 (Santa Cruz Biotechnology). The antibody isotype controls were mouse IgG (BD Biosciences) and rabbit IgG (Abcam). The secondary antibody was PE-labeled goat anti-rabbit IgG (1:50; Jackson Immunoresearch Labs). Experiments were repeated at least twice to confirm results.
SKOV3 human ovarian carcinoma cells (American Type Culture Collection) were infected with 100 multiplicities of infection of an adenovirus vector expressing murine endosialin. Others have found 77.5% identity between human and murine endosialin and 100% identity between the transmembrane portion of the human and murine proteins (25) . The cDNA of murine endosialin was cloned into an adenovirus shuttle vector DC67 by way of EcoRI and XhoI. The DC67 construct was digested with I-CEU to isolate the murine endosialin cDNA, cytomegalovirus promoter region, and BGH poly(A) region fragment. This fragment was cloned into the I-CEU site of a DC71 vector. The DC71 construct encoding murine endosialin was digested with SnbaI to generate linear DNA, which was used to transfect 293 cells for virus production. SKOV3 cells were cultured in RPMI 1640/10% FBS for 72 h with virus.
In vitro Tube Formation Matrigel (BD Biosciences) was added to a 48-well plate (150 AL/well). Hybridoma-produced monoclonal antibodies in PBS were mixed with EPC in IMDM with 10% FBS (final concentrations: 2% FBS, 80% PBS, and 18% IMDM). EPC (2.5 Â 10
3 ) and antibodies were preincubated for 45 min before seeding on Matrigel in 300 AL. The antibody concentration was 120 Ag/mL. Inhibition of tube formation was observed in six independent experiments. HMVEC and HUVEC were conducted in endothelial cell basal medium/2% FBS. The tube networks were stained with calcein (4 Ag/mL) for 30 min at 37jC and quantified by image analysis using Scion image (NIH) as fluorescent pixel area. Samples were assayed in triplicate.
Migration Assay EPC (5 Â 10 4 cells) were placed into the upper chamber of a FluoroBlok insert with 8 Am pores (BD Biosciences) in serum-free IMDM (300 AL) for 48 h. The inserts were placed into the lower chamber wells of a 24-well plate containing IMDM/0.5% FBS as chemoattractant. The rabbit polyclonal anti-endosialin antibody or rabbit antibody control was added to both the insert and lower well to a final concentration of 800 Ag/mL. Because the rabbit anti-endosialin is purified over a column that binds IgG and is not specific for anti-endosialin, this concentration reflects the total amount of IgG in the prep and not only anti-endosialin. After 48 h, EPC in the lower chamber were stained with calcein (4 Ag/mL; Molecular Probes) in PBS for 30 min at 37jC and fluorescence was quantified using a fluorometer set at 485 nm excitation and 530 nm emission. Data are expressed as number of cells that migrated F SD (n = 3). Before the migration assay, EPC were preincubated with the antibodies (800 Ag/mL) overnight in serum-free medium. Migration assays have been done six times with inhibitory effects observed.
In vivo Matrigel Assay EPC were labeled with 4 ¶,6-diamidino-2-phenylindole (20 Ag/mL; Sigma) at 37jC for 20 min and washed twice with PBS. EPC (5 Â 10 5 ) in PBS (100 AL) were mixed with Matrigel (500 AL; BD Biosciences) containing 40 units/mL heparin and 150 ng/mL bFGF. The Matrigel containing EPC (500 AL) were implanted s.c. into the middorsal region of female BALB/c nude mice (CAnN.CgFoxn1 nu /Crl, Charles River Laboratories). The Matrigel plugs containing EPC were collected after 7 days and snap frozen in OCT medium. For detection of human endosialin, sections were fixed for 10 min in zinc-formaldehyde (EMS), blocked with 10% goat serum, and incubated at room temperature with 10 Ag/mL biotinylated monoclonal anti-endosialin from hybridomas. Samples were washed with TBS, incubated for 30 min at room temperature with streptavidin-Cy3 (Jackson Immunoresearch), washed, mounted with Antifade mounting medium, and imaged using Metamorph acquisition software (Molecular Devices). Experiments were done twice with consistent results.
In vivo SKNAS/c-EPC Model The SKNAS cells were collected when in exponential growth phase and 5 Â 10 6 cells were injected in 1:1 RPMI 1640/Matrigel (100 AL) in the flank region of female nude mice age 6 to 8 weeks (CD1 nu/nu, Charles River Laboratories) on day 0. In a single experiment, CHOderived monoclonal anti-endosialin or control antibodies (25 mg/kg) in physiologic saline were administered i.v. via the tail vein on days 7 and 9 when the tumors were 80 to 100 mm 3 . On day 11, blood was collected by cardiac puncture into EDTA-containing tubes from three mice per group. Cells per milliliter of blood were counted using a ViCell automated cell counter (Beckman Coulter). For blood leukocyte counting, 20 AL whole mouse blood was combined with 480 AL Versalyse (Beckman Coulter) and live blood leukocytes were enumerated using a Vi-Cell automated cell counter (Beckman Coulter). Lysis of RBC in the remainder of the whole blood sample was done by incubating the sample with at least a 5-fold excess RBC lysing solution (Sigma) for 20 min at room temperature. Remaining blood cells were centrifuged and washed before addition of antibodies. Antibodies used for endothelial cell detection included FITC anti-CD13, PE anti-VEGFR2, PerCP or PerCP-Cy7 anti-CD45, and APC anti-CD117 (BD Biosciences). The anti-CD117 antibody was used to distinguish EPC from endothelial cells. Additional markers reported to be expressed by endothelial cells were also examined including PE anti-CD202 (Tie-2; EBiosciences), anti-CD144 (VE-cadherin) with secondary PE anti-rat IgG (BD Biosciences), FITC anti-CD201 (Stem Cell Technologies), and PE anti-CD61 (BD Biosciences). Propidium iodide (BD Biosciences) excluded dead cells. Cell staining for specific markers was determined by flow cytometric analysis (FACSCalibur and FACSCanto, BD Biosciences). Given the low volumes of blood available and the high number of cells required for this analysis, isotype controls for were done for VEGFR2 and CD117 but not for CD45 and CD13 on samples from this experiment. These controls have been done in previous experiments and showed minimal background staining.
Results
There is no single molecular marker that denotes an EPC, but rather a panel of markers serves to distinguish EPC and confirm differentiation along an endothelial cell lineage. EPC were derived from CD34 + /CD133 + bone marrow cells and on exposure to VEGF/bFGF/heparin up-regulated the expression of CD31, VEGFR2, and VE-cadherin but not CD45, a marker of hematopoetic cells (Fig. 1A) . EPC were capable of acetylated LDL uptake, an endothelial cell trait. After confirmation that EPC presented the expected endothelial cell phenotype, EPC were subsequently evaluated for the expression of markers up-regulated by tumor endothelial cells, TEM.
Preliminary data linking EPC and endosialin became evident on SAGE analysis. Two SAGE libraries from EPC maintained under either nonstimulatory or stimulatory (VEGF) conditions resulted in the identification of 18,710 and 20,277 unique tags, respectively (Fig. 1B) . Thirty of the 46 TEM identified in colon tumor endothelium were present in the EPC libraries. Endosialin (TEM1) mRNA was one of 23 of 46 TEM present in both libraries (3) . Of the remaining SAGE tags, approximately one-third were found in both VEGF-stimulated and unstimulated libraries, highlighting the significant effect of VEGF exposure on gene expression in EPC. Sixteen of the 46 TEM identified in colon tumor endothelium were not found in the EPC libraries. These markers may reflect either the differences between cell culture and in vivo gene expression of EPC. Alternatively, TEM not reflected in EPC but present in tumor vasculature may reflect coisolation of pericytes or represent endothelial cells derived from nearby host blood vessels in the original study.
The more primitive starting population of CD133 + / CD34 + bone marrow progenitor cells express nondetectable levels of endosialin mRNA. Nonadherent bone marrow progenitor cells exposed to VEGF/bFGF in fibronectin or collagen-coated plates also did not express endosialin mRNA. However, the adherent subpopulation of cells from these cultures after 3 to 4 weeks in culture with continuous exposure to VEGF/bFGF on either substratum express endosialin mRNA ( Fig. 2A) . Studies looking into the effects of VEGF/bFGF/heparin on endosialin mRNA expression in propagated cultures EPC indicated that the presence or absence of these growth factors did not have a significant effect once the CD133 + /CD34 + bone marrow cells had differentiated into EPC (data not shown).
The levels of endosialin mRNA in EPC were compared with the expression of several other TEM by these cells (Fig. 2B) . The mRNA for ANTXR1/TEM8 and TEM9 were expressed at levels higher than endosialin mRNA, whereas TEM3, TEM5, and TEM6 were expressed at lower levels and TEM7 mRNA was barely detectable. Expression of endosialin by EPC and HMVEC were compared by SAGE analysis. Levels of endosialin mRNA were found to be 10-fold higher in EPC (10-14 copies) than in HMVEC (1 copy), consistent with the notion that a mature endothelial cell from normal vasculature would not express a TEM (data not shown). By reverse transcription-PCR analysis, although there is some heterogeneity, endosialin mRNA levels in EPC from three individual donors are significantly higher than endosialin mRNA levels in HMVEC (P < 0.05; Fig. 2C ). The comparison suggests that EPC are more representative of tumor endothelium than HMVEC and that EPC may contribute to early events of tumor angiogenesis. To confirm endosialin protein expression, EPC were analyzed using a rabbit polyclonal IgG to endosialin. For comparison, endosialin protein expression was also investigated in HMVEC and HUVEC. Flow cytometry analysis indicated a higher level of expression of endosialin in EPC than in HMVEC or HUVEC (Fig. 3A) . Thus, the protein expression findings were consistent with SAGE and reverse transcription-PCR results obtained with mRNA from EPC and HVMEC. Because EPC are a more immature progenitor cell, endosialin expression may be necessary to guide differentiation and subsequent neovascularization under angiogenic conditions as would be expected with tumor growth. Endosialin expression has not been observed in resting or activated HUVEC but was overexpressed in HUVEC that were immortalized (26) . The protein expression of other TEM was investigated in EPC by flow cytometry (Fig. 3B) . Cell surface expression of TEM2, TEM4, TEM5, and TEM8 were detected with greater levels of TEM8. There was no protein expression of TEM7. Immunostaining of endosialin in adherent EPC was carried out using a rabbit polyclonal antibody to endosialin and a fluorescently labeled secondary antibody (Fig. 3C) . Endosialin protein is localized to the cell surface as expected (4) . The antibody generated to endosialin had great affinity for EPC and therefore was tested in functional assays.
EPC perform well in assays in culture used to model neovascularization including tube formation and migration. These cellular functions can be quantified in culture as a measure of potential angiogenic or antiangiogenic activity. Migration of endothelial cells through tissues is necessary in homing to areas of angiogenic stimuli. Disruption of this process may retard blood vessel development during tumor neovascularization. EPC were placed into upper chambers with porous membranes that allow migration of cells toward a chemoattractant, serum, in the lower chamber. The addition of the rabbit polyclonal anti-endosialin antibody to both upper and lower chambers ensured that EPC were continuously exposed to antiendosialin. Exposure to anti-endosialin inhibited EPC activity in the migration assay by f65% (P = 0.009; Fig. 4A ). EPC form networks or tubes similar to those of HMVEC and HUVEC on Matrigel in culture (21) . When exposed to a hybridoma-produced monoclonal anti-endosialin antibody, EPC were incapable of generating capillary-like structures compared with control following an overnight incubation ( Fig. 4B and C) . EPC were preincubated with the antibodies before being seeded on Matrigel to allow for sufficient binding before initiation of the tube formation process and adherence of the cells to the matrix. Image analysis software was used to measure the length of the tubes and provide a quantitative readout. The area of EPC tube formation was significantly decreased by f85% when the EPC were exposed to anti-endosialin (P < 0.05). By comparison, the anti-endosialin did not inhibit HMVEC or HUVEC tube formation.
When EPC were incorporated into a Matrigel plug angiogenesis assay in immunodeficient mice, EPC continued to express endosialin (Fig. 5 ). EPC were prelabeled with the nuclear stain 4 ¶,6-diamidino-2-phenylindole to distinguish between human EPC and invading host cells. In this model system, EPC express the cell surface proteins, von Willebrand factor and CD31 (21) . The alignment of EPC under the proangiogenic conditions in the Matrigel plug is indicative of the potential of EPC to contribute to neovessel formation.
The ability of CHO-produced monoclonal anti-endosialin to influence EPC in vivo was investigated in the SKNAS neuroblastoma xenograft model. Binding of the antiendosialin antibody to the murine homologue of endosialin was confirmed using SKOV3 ovarian carcinoma cells infected with an adenovirus expressing the murine homologue of endosialin (Fig. 6A) . S.c. SKNAS xenograft tumors were 200 to 300 mm 3 in volume when blood samples were collected. The antigen CD117 was used to distinguish EPC from endothelial cells (Fig. 6B) . Circulating levels of host endothelial cells and EPC were confirmed to be higher in tumor-bearing mice than in naive mice by four-color flow cytometry (Fig. 6C) . I.v. administration of anti-endosialin to the tumor-bearing mice significantly decreased the number of circulating EPC (c-EPC) compared with mice that received a control antibody. Thus, targeting endosialin in a model system of cancer can lead to a reduction of a + bone marrow progenitor cells and differentiated EPC. Endosialin expression increased as cells differentiated from bone marrow progenitor cells to adherent EPC (P < 0.05). B, when the mRNA expression of endosialin/TEM1 and other TEM were quantified TEM1, TEM8, and TEM9 were most highly expressed followed by TEM3, TEM5 and TEM6; TEM7 was detected at negligible levels. C, when EPC and HMVEC were analyzed for endosialin mRNA, endosialin was more highly expressed by EPC than by HMVEC (P < 0.05). Data are expressed as number of transcripts per reaction, normalized to 18S.
precursor cell population, EPC, in circulation. Although the levels of circulating endothelial cells (c-EC) appeared to be diminished by the anti-endosialin as well, this result was not statistically significant. However, there was no reduction in tumor volume in mice that received the antiendosialin antibodies, suggesting that EPC are not critical to the development of blood vessels in SKNAS s.c. tumors and do not substantially promote the growth of primary tumors in this particular model. The lack of efficacy may also be attributed to little detection by immunohistochemical methods of endosialin in the established vasculature of SKNAS tumors (data not shown) despite positive expression in the immature EPC.
Discussion
EPC have emerged as an intriguing component of malignant neovascularization of some cancers, such as multiple myeloma and non-small cell lung cancer (17, 18) . Although endosialin mRNA and protein are detectable at low levels in mature endothelial cells such as HMVEC and HUVEC when grown in culture, the induction of endosialin expression in EPC and the absence of endosialin in the starting population of bone marrow progenitor cells suggest that endosialin is involved in early stages of endothelial cell differentiation in response to proangiogenic conditions. EPC have value as a better model of tumor endothelium than are HMVEC or HUVEC because EPC more readily express endosialin that is overexpressed in the blood vessels of malignant tissues and EPC can be incorporated in assays for drug development. EPC also express other TEM, particularly TEM4 and TEM8. Endosialin expression that we have discovered in EPC presents value for the field of oncology because endosialin has been readily detected in human tumors of several Figure 3 . A, different endothelial cell types were immunofluorescently stained for endosialin protein expression and analyzed by flow cytometry using the rabbit polyclonal anti-endosialin antibody. Endosialin protein is more highly expressed in EPC than in either HMVEC or HUVEC. B, expression of other TEM by EPC revealed that EPC also express TEM2, TEM4, TEM5, and TEM8 but not TEM7. C, EPC expressing endosialin were stained with a rabbit polyclonal anti-endosialin. Cell surface labeling of endosialin on EPC is evident compared with EPC incubated with preimmune rabbit serum.
pathologies. In primary brain tumors metastasis, endosialin colocalized with CD31 + endothelial cells and Thy-1 + or a-SMA + cells associated with vasculature (9) . The largest proportion of endosialin-expressing tumors were glioblastoma multiforme, anaplastic astrocytomas, and brain metastasis from carcinomas. Endosialin was expressed by melanoma, oligodendrogliomas, astrocytomas, meningiomas, and ependymomas. SAGE analysis on endothelial cells derived from fresh surgical samples of normal temporal lobe cortex or gliomas revealed 16 genes highly up-regulated in tumor endothelial cells compared with normal endothelial cells and endosialin was among these genes (23) . Brain tumors are highly vascularized and the overexpression of endosialin both in this disease and in EPC support previous observations that EPC may contribute in part to the tumor vasculature due to a tropism for brain tumors (27, 28) .
A similar correlation with disease progression and endosialin expression (and TEM8, also highly expressed by EPC in our study) was observed in breast cancer (29) . Most normal human tissues were negative for endosialin, whereas 41 of 61 sarcomas, 26 of 37 carcinomas, and 18 of 25 neuroectodermal tumors were endosialin positive by immunohistochemistry (4) . Several recent reports have detected endosialin mRNA and/or endosialin protein in various tumor settings. Examination of human breast cancer (n = 120) and normal breast tissues (n = 33) found that elevated levels of endosialin were associated with either nodal involvement and/or disease progression, a potentially prognostic value in breast cancer (29) . Preclinical studies of breast cancer in mice have shown that bone marrow -derived endothelial cells can incorporate into the blood vessels (13) . The EPC in this study were derived from bone marrow and the link between endosialin expression in EPC and in breast cancer progression supports the hypothesis that cells from the bone marrow can contribute to tumor vasculature.
It should be noted that the significance of EPC involvement in tumor development can be a controversial topic. Efforts to quantify the degree of EPC contribution to human or murine tumor endothelium have generated low numbers ranging from 2% to 15% in clinical human biopsies and in some murine models (30 -32) . In the experiment described here, a significant reduction in c-EPC did not inhibit the growth of SKNAS tumors and this result could be attributed to several factors. For Figure 4 . A, EPC were incorporated into a transwell migration assay with the rabbit polyclonal anti-endosialin or with the control antibody. After 48 h, EPC migration was quantified by staining migrated cells with calcein and measuring fluorescence. EPC migration was inhibited by the polyclonal antiendosialin (P = 0.009). Mean F SD (n = 3). B and C, effect of the hybridoma-produced monoclonal anti-endosialin antibody on EPC tube formation on Matrigel was evaluated. Tube formation was significantly decreased in the presence of the anti-endosialin compared with IgG control (P < 0.05). The final antibody concentration was 120 Ag/mL. The anti-endosialin antibody had no effect on HMVEC or HUVEC tube formation. Mean F SD (n = 3).
example, the degree of EPC involvement of tumor vasculature can vary depending on the grade of tumor, tumor type, or vary between strains of mice (31, 33) . Alternatively, EPC may have greater influence on tumor vasculature in preclinical models depending on whether the tumor is s.c. or orthotopic or are metastatic lesions. The elevated numbers of c-EPC, however, were apparent in tumor-bearing mice compared with naive animals. An increase in c-EC was also observed in mice with SKNAS tumors that may have been shed from tumor vasculature, yet the decrease in numbers following anti-endosialin administration was not as meaningful.
Several reports have described results indicating that EPC blockade can inhibit tumor growth. Continuous infusion of endostatin, a fragment of collagen XVIII, reduced EPC mobilization from the bone marrow and reduced or abrogated Namalwa and Granta 519 human lymphoma tumor growth in immunodeficient mice (34) . In Id1 +/-Id3 -/-mutant mice, bone marrow -derived EPC recruitment to B6RV2 lymphoma or Lewis lung tumors is impaired resulting in diminished tumor growth (35) . A marked delay in the growth of Lewis lung tumors was also achieved with an anti-VE-cadherin antibody that selectively targeted EPC but not endothelial cells (36) . Importantly, this study also showed that the EPC were most crucial at the earliest stages of angiogenesis.
Although opposing points of view have been expressed on the relevance of and characteristics that define EPC, c-EPC exist and were reported in several clinical settings. Elevated c-EPC levels correlated with increased serum VEGF, erythropoietin, and angiopoietin-2 in breast cancer patients (37) . Levels of c-EPC were increased in patients with gliomas versus healthy donors or those suffering recent ischemic strokes (38) . Higher levels of c-EPC were also detected in patients with hepatocellular carcinoma versus healthy controls (39) . The number of endosialinexpressing cells in circulation may be a useful biomarker/ surrogate marker for the development and/or use of antiangiogenic therapies. In concert with other molecular markers such as CD34, CD133, and VEGFR2, the detection of endosialin protein would be advantageous in distinguishing c-EPC from c-EC using multicolor flow cytometry.
In non-small cell lung cancer cases, c-EPC numbers were increased before treatment, correlated with poor overall survival, and were significantly reduced in patients who responded to therapy (18) . The progression of lung metastasis by EPC in preclinical models has led to the proposal that selective targeting of EPC in lung cancer patients may be beneficial (14) . Given that the data generated by Goa et al. indicate that the blockade of bone marrow -derived EPC does not prevent the initial seeding of metastatic lesions in the lung but rather inhibits the development of micrometastasis to macrometastasis, we predict that an anti-endosialin antibody would exert similar effects and delay the progression of disease in the lung until the malignant cells are able to compensate by recruiting resident progenitor cells, for example.
The protein structure of endosialin revealed by EPC in this study places it in the Group XIV thrombomodulin-like family of C-lectin domain proteins (40) . However, the absence of expression of endosialin in mature, normal endothelium differentiates it from thrombomodulin. The function of endosialin has been implicated with attachment and adhesion to extracellular matrix proteins (6) and the expression pattern of this protein in solid tumors may make it a favorable target for cancer therapy with an antibody or antibody-toxin conjugate. In an alternative strategy, a single-chain antibody fragment directed toward the endosialin extracellular domain was used to guide a liposomeencapsulated cytotoxic agent to tumor vasculature with favorable results (41) .
Using EPC with the expression of endosialin as a molecular marker in conjunction with other markers associated with EPC to distinguish these cells from other cells of the vasculature or in circulation would add relevance and possibly more predictable information that would subsequently lead to a more optimal treatment regime that has been lacking thus far (42) . Bolus administration of cytotoxics or vascular-disrupting agents can result in an acute mobilization of EPC that may be associated with disease relapse (43, 44) . Close monitoring of patients' responses to treatment by measuring c-EPC levels could improve patient outcome and guide the development of more effective therapies. The results presented in this article support the proposal that endosialin and EPC hold potential value both as diagnostic markers and as putative targets for interventive therapies. 
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